BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

Mills, W; Chopra, Rajesh; McMillan, Andrew; Pearce, R; Linch, David C.; Goldstone, AH

doi:10.1200/jco.1995.13.3.588

Cited by 288 publications

(242 citation statements)

References 11 publications

Supporting

Mentioning

218

Contrasting

Unclassified

Order By: Relevance

“…11 Toxicities of BCNU-containing regimens, such as BEAM and BEAC, are concerning for a high incidence of interstitial pneumonitis. 12,13 Furthermore, results from the Bone Marrow Transplant Survivor Study have shown a significantly increased rate of non-relapse related mortality after autologous SCT for hematologic malignancies with BCNU-based regimens that was not observed with BU-or TBI-based regimens. 14 At risk: Few series using BU/CY as the conditioning regimen for autologous SCT in patients with relapsed NHL have been reported.…”

Section: Discussionmentioning

confidence: 99%

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

Escalón

Stefanovic

Venkatraman

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

High-dose chemotherapy with autologous SCT has become standard of care for patients with relapsed aggressive non-Hodgkin's lymphoma (NHL). To improve safety and efficacy of this treatment, new conditioning regimens are being developed. We retrospectively reviewed clinical data of patients with relapsed NHL treated at our institution with i.v. BU and CY (BU/CY) as conditioning regimen for autologous SCT between January 2000 and April 2005. We identified 43 patients (24 men, 19 women, median age 50) with diffuse large B-cell lymphoma (n ¼ 28), follicular lymphoma (n ¼ 8), mantle cell lymphoma (n ¼ 4) and peripheral T-cell lymphoma (n ¼ 3). Following salvage chemotherapy, there were 26 complete responses, 13 partial responses and 4 stable diseases. Median time to neutrophil and platelet recovery was 11 and 13.5 days, respectively. Treatmentrelated toxicities included nausea/vomiting, diarrhea and mucositis. The 100-day mortality was 9%: sepsis (n ¼ 1), pneumonia (n ¼ 1) and hepatic veno-occlusive disease (n ¼ 2). Twenty-one patients were followed until death and twenty-one surviving patients were followed for a median of 29 months (range 0.4-76). Three-year estimates of event-free survival, progression-free survival and overall survival were 35, 39 and 43%, respectively. We conclude that i.v. BU/CY is a safe and effective conditioning regimen for autologous SCT in relapsed NHL.

show abstract

Section: Discussionmentioning

confidence: 99%

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

Escalón

Stefanovic

Venkatraman

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…The overall survival at the time of transplantation was 93% for chemosensitive patients and 0% for chemoresistant patients (P<0.0001). Mills et al (18) reported a five-year progression-free survival of 49% for 55 chemosensitive patients with NHL, and 10% for 42 patients with chemoresistant lymphoma treated with HDT and ABMT. The main issue of this study is related to the important impact of HDCY on the diseases: 57.6% of patients achieved complete remission, 19 of 23 chemosensitive patients and 2 of 10 chemoresistant patients.…”

Section: Discussionmentioning

confidence: 99%

“…Thirty-one patients underwent HDT. These patients received a 6-day period of chemotherapy according to the BEAM protocol (18). PBPC were re-infused on the day following HDT, nominally day 0 of the transplant procedure.…”

Section: High-dose Therapy and Autologous Bone Marrow Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Baldissera

Aranha

Oliveira

et al. 2002

Braz J Med Biol Res

View full text Add to dashboard Cite

Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin s disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin s lymphoma (NHL) (60.6%) or persistent or relapsed Hodgkin s disease (39.4%) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin s disease) followed by autologous PBPC transplantation. On an intention to treat basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10 6 /kg (1.07-29.3) CD34 + cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15%, respectively (P<0.0001). Overall survival was 92% for chemosensitive patients and 0% for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12% (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin s disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin s disease, with acceptable mortality rates related to sequential treatment.

show abstract

“…1) to 17% (ref. 4), depending on definition, but the risk of pneumonitis in patients with pre-existing lung disease is unknown. Our practice has been to omit BCNU when pre-transplant lung function tests showed a lung carbon monoxide transfer coefficient (KCO) of less than 50% or when there was pre-existing lung disease.…”

mentioning

confidence: 99%

Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis

Loke

Ward

Mahendra

et al. 2013

Bone Marrow Transplant

View full text Add to dashboard Cite

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

Abstract: Patients with chemosensitive disease benefit most from high-dose chemotherapy, and those who receive such therapy early after achieving a partial response to first-line therapy have a high rate of cure.

Cited by 288 publications

References 11 publications

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis

Contact Info

Product

Resources

About